据报阿斯利康料疫情最早明年7月结束 可从疫苗中获利
英国《金融时报》引述药厂阿斯利康(AZN.US)与巴西卫生部旗下科研协会Fiocruz的备忘录报道,阿斯利康预计最早可能在明年7月从新型冠状病毒疫苗中获利。
阿斯利康此前表示不会在疫情期间从疫苗中获利,该备忘录显示阿斯利康可以宣布疫情何时结束。
阿斯利康发表声明指,今次研发疫苗是基於应对全球公共卫生突发事件,而不是将今次疫情视为商业机会,公司目前疫苗生产能力已超过30亿剂,并已建立多个供应链,以确保低收入国家亦能及时及公平地获得疫苗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.